Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:05 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 310 matching trials from the live ClinicalTrials.gov search.

Filters: "ALK" Clear all

Conditions: Anaplastic Large Cell Lymphoma, Recurrent Childhood Anaplastic Large Cell Lymphoma
Interventions: monoclonal antibody SGN-30, therapeutic hydrocortisone, ifosfamide, carboplatin, etoposide, methotrexate, cytarabine, pharmacological study, laboratory biomarker analysis; Biological · Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 1 Year to 21 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Neoplasms
Interventions: Alectinib, Crizotinib; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: Not listed
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 2
States / cities: Orange, California • Boston, Massachusetts

Conditions: Metastatic NSCLC
Interventions: GRN-1201 + Pembrolizumab; Biological
Lead sponsor: BrightPath Biotherapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 11
States / cities: Orange, California • Aurora, Colorado • Orlando, Florida + 7 more

Conditions: ALK-positive Advanced Tumors
Interventions: ceritinib, warfarin, midazolam; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 3
States / cities: Detroit, Michigan • San Antonio, Texas

Conditions: Non-Small Cell Lung Cancer
Interventions: Avelumab, PF-06463922, Crizotinib; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 7
States / cities: Atlanta, Georgia • Boston, Massachusetts • Nashville, Tennessee

Conditions: Lymphoma, T-Cell, Lymphoma, Extranodal NK-T-Cell
Interventions: Alemtuzumab (Campath), EPOCH; Biological · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 17 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2021
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Advanced Non-small Cell Lung Cancer
Interventions: REGN2810, Platinum-doublet chemotherapy; Drug · Other
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Tarrytown, New York

Conditions: Diffuse Large B-Cell Lymphoma, B-cell Non-Hodgkin's Lymphoma
Interventions: Debio 1562, Rituximab; Drug
Lead sponsor: Debiopharm International SA; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 9
States / cities: Birmingham, Alabama • Urbana, Illinois • Minneapolis, Minnesota + 6 more

Conditions: Cancer, Advanced Solid Tumor
Interventions: lorlatinib, encorafenib + binimetinib, talazoparib, sacituzumab govitecan, axitinib, Fam-Trastuzumab Deruxtecan-Nxki, enfortumab vedotin; Drug
Lead sponsor: Strata Oncology; Industry
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 4
States / cities: St. Petersburg, Florida • Tallahassee, Florida • Kettering, Ohio + 1 more

Conditions: Non-Small Cell Lung Cancer
Interventions: Osimertinib, Savolitinib, Gefitinib, Necitumumab, Durvalumab, Carboplatin, Pemetrexed, Alectinib, Selpercatinib, Selumetinib, Etoposide, Cisplatin, Datopotamab deruxtecan; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 247 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 16
States / cities: Duarte, California • Los Angeles, California • Sacramento, California + 11 more

Conditions: Relapsed Neuroblastoma, Refractory Neuroblastoma, High-risk Neuroblastoma
Interventions: Autologous hALK.CAR T cells; Biological
Lead sponsor: Roberto Chiarle; Other
Eligibility: 12 Months to 29 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Capmatinib; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 373 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 13
States / cities: Long Beach, California • Los Angeles, California • Orange, California + 10 more

Conditions: Non-small Cell Lung Cancer, Lung Cancer, Advanced Malignancies, Carcinoma
Interventions: Brigatinib, Crizotinib; Drug
Lead sponsor: Ariad Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 275 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 12
States / cities: Sedona, Arizona • Bellflower, California • Aurora, Colorado + 9 more

Conditions: HIV Coinfection
Interventions: Maraviroc, Placebo; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years and older
Enrollment: 138 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 24
States / cities: Bakersfield, California • Los Angeles, California • Oakland, California + 16 more

Conditions: Advanced Cancer, Advanced Solid Tumors
Interventions: ALK201; Drug
Lead sponsor: Shanghai Allink Biotherapeutics Co., Ltd.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 202 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 4
States / cities: Denver, Colorado • Orlando, Florida • New Orleans, Louisiana + 1 more

Conditions: Leishmaniasis
Interventions: Sodium Stibogluconate (SSG); Drug
Lead sponsor: U.S. Army Medical Research and Development Command; Federal
Eligibility: Not listed
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2015
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Infections, Bacterial
Interventions: Gepotidacin, Cimetidine, Rifampicin, Midazolam, Digoxin, Placebo matching to gepotidacin; Drug · Other
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Not listed
Lead sponsor: US Oncology Research; Industry
Eligibility: 18 Years and older
Enrollment: 7,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 17
States / cities: Daphne, Alabama • Prescott Valley, Arizona • Denver, Colorado + 14 more

Conditions: ALK-positive Advanced NSCLC
Interventions: Crizotinib, Pembrolizumab; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 15
States / cities: Birmingham, Alabama • Duarte, California • La Jolla, California + 4 more

Conditions: Anaplastic Large Cell Lymphoma, ALK-Positive, Ann Arbor Stage II Noncutaneous Childhood Anaplastic Large Cell Lymphoma, Ann Arbor Stage III Noncutaneous Childhood Anaplastic Large Cell Lymphoma, Ann Arbor Stage IV Noncutaneous Childhood Anaplastic Large Cell Lymphoma
Interventions: Brentuximab Vedotin, Crizotinib, Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin Hydrochloride, Etoposide, Ifosfamide, Methotrexate; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Up to 21 Years
Enrollment: 137 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2024
U.S. locations: 154
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 117 more

Conditions: Non Small Cell Lung Cancer, CNS Progression
Interventions: Temozolomide plus Osimertinib, Temozolomide plus Lorlatinib; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Ganglioneuroblastoma, Stage 1 Neuroblastoma, Stage 2 Neuroblastoma, Stage 2A Neuroblastoma, Stage 2B Neuroblastoma, Stage 3 Neuroblastoma, Stage 4 Neuroblastoma, Stage 4S Neuroblastoma
Interventions: Autologous Hematopoietic Stem Cell Transplantation, Busulfan, Cisplatin, Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide, External Beam Radiation Therapy, Filgrastim, Laboratory Biomarker Analysis, Melphalan, Mesna, Peripheral Blood Stem Cell Transplantation, Pharmacological Study, Topotecan Hydrochloride, Vincristine Sulfate; Procedure · Drug · Radiation + 2 more
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 30 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2024
U.S. locations: 113
States / cities: Birmingham, Alabama • Downey, California • Duarte, California + 90 more

Conditions: Lung Cancer
Interventions: Carboplatin, Nivolumab, pemetrexed, Ipilimumab; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 3
States / cities: Boston, Massachusetts

Conditions: Stargardt Disease
Interventions: ALK-001, Placebo; Drug
Lead sponsor: Alkeus Pharmaceuticals, Inc.; Industry
Eligibility: 8 Years to 45 Years
Enrollment: 230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 14
States / cities: Phoenix, Arizona • Aurora, Colorado • Gainesville, Florida + 11 more

Search by objective public record fields.

Ifosfamide, Carboplatin, Etoposide, and SGN-30 in Treating Young Patients With Recurrent Anaplastic Large Cell Lymphoma

A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer

GRN-1201 With Pembrolizumab in Subjects With Metastatic PD-L1+ NSCLC

A Phase I, Multi-center, Open Label, Drug-drug Interaction Study to Assess the Effect of Ceritinib on the Pharmacokinetics of Warfarin and Midazolam in Patients With ALK-positive Advanced Tumors

Study to Evaluate Safety, Efficacy, Pharmacokinetics And Pharmacodynamics Of Avelumab In Combination With Either Crizotinib Or PF-06463922 In Patients With NSCLC. (Javelin Lung 101)

Campath-1H and EPOCH to Treat Non-Hodgkin's T- and NK-Cell Lymphomas

Evaluation of Cemiplimab in Combination With Platinum-Doublet Chemotherapy in First-Line (1L) Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) in Adult United States (US) Participants

Study to Evaluate the Efficacy and Tolerability of Debio 1562 in Combination With Rituximab in Participants With Relapsed and/or Refractory DLBCL and Other Forms of NHL

StrataPATH™ (Precision Indications for Approved Therapies)

Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)

Study of hALK.CAR T Cells for Patients With Relapsed/Refractory High-risk Neuroblastoma

Study of Oral cMET Inhibitor INC280 in Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1)

ALTA-1L Study: A Study of Brigatinib Versus Crizotinib in Anaplastic Lymphoma Kinase Positive (ALK+) Advanced Non-small Cell Lung Cancer (NSCLC) Participants

A Study Of Maraviroc In HIV Co-Infected Subjects With Hepatitis C And/Or Hepatitis B

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK201 in Participants With Advanced Solid Tumors

Use of Sodium Stibogluconate as a Treatment for Leishmaniasis

Drug-drug Interaction Study of Gepotidacin

MYLUNG Consortium Part 3: Observational Study

Crizotinib Plus Pembrolizumab In Alk-Positive Advanced Non Small Cell Lung Cancer Patients

Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma

Temodar Plus Tyrosine Kinase Inhibitors for Progressive CNS Disease

Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma

Nivolumab in Combination With Chemotherapy, or Nivolumab in Combination With Ipilimumab, in Advanced EGFR-Mutant or ALK-Rearranged NSCLC

Study of ALK-001 on the Progression of Stargardt Disease